ATE546132T1 - Prozess zur veränderung der kristallform von mycophenolat natrium salz - Google Patents

Prozess zur veränderung der kristallform von mycophenolat natrium salz

Info

Publication number: ATE546132T1
Authority: AT; Austria
Prior art keywords: changing; sodium salt; crystal form; mycophenolate sodium; mycophenolate
Prior art date: 2003-01-20

Application number

AT04703158T

Other languages

English (en)

Inventor

Sabine Pfeffer

Dierk Wieckhusen

Original Assignee

Novartis Ag

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-20

Filing date

2004-01-19

Publication date

2012-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE546132(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-01-19 Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE546132T1 publication Critical patent/ATE546132T1/de

Links

HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical class OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Furan Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Saccharide Compounds (AREA)

AT04703158T 2003-01-20 2004-01-19 Prozess zur veränderung der kristallform von mycophenolat natrium salz ATE546132T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0301259.8A GB0301259D0 (en)	2003-01-20	2003-01-20	Organic compounds
PCT/EP2004/000354 WO2004064806A2 (en)	2003-01-20	2004-01-19	Process for modifying drug crystal formation

Publications (1)

Publication Number	Publication Date
ATE546132T1 true ATE546132T1 (de)	2012-03-15

Family

ID=9951448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04703158T ATE546132T1 (de)	2003-01-20	2004-01-19	Prozess zur veränderung der kristallform von mycophenolat natrium salz

Country Status (31)

Country	Link
US (3)	US20060122265A1 (de)
EP (2)	EP2308471A1 (de)
JP (1)	JP4549976B2 (de)
KR (5)	KR20100120321A (de)
CN (2)	CN101333201A (de)
AR (2)	AR043343A1 (de)
AT (1)	ATE546132T1 (de)
AU (1)	AU2004206731B2 (de)
BR (1)	BRPI0406827A (de)
CA (2)	CA2706900A1 (de)
CL (1)	CL2004000073A1 (de)
CO (1)	CO5580738A2 (de)
CY (1)	CY1112772T1 (de)
DK (1)	DK1592401T3 (de)
EC (1)	ECSP055918A (de)
ES (1)	ES2382035T3 (de)
GB (1)	GB0301259D0 (de)
IL (1)	IL169484A (de)
MX (1)	MXPA05007691A (de)
MY (1)	MY148297A (de)
NO (1)	NO20053846L (de)
NZ (1)	NZ541073A (de)
PE (2)	PE20110276A1 (de)
PL (2)	PL376525A1 (de)
PT (1)	PT1592401E (de)
RU (1)	RU2388757C2 (de)
SG (1)	SG155046A1 (de)
SI (1)	SI1592401T1 (de)
TW (1)	TWI325785B (de)
WO (1)	WO2004064806A2 (de)
ZA (1)	ZA200504442B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0124953D0 (en)	2001-10-17	2001-12-05	Novartis Ag	Organic Compounds
GB0301259D0 (en)	2003-01-20	2003-02-19	Novartis Ag	Organic compounds
AR045957A1 (es) *	2003-10-03	2005-11-16	Novartis Ag	Composicion farmaceutica y combinacion
WO2005105768A2 (en)	2004-04-26	2005-11-10	Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg	Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es)	2004-04-27	2007-04-10	Teva Gyogyszergyar Zartkoruen	Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
TWI322147B (en)	2004-07-20	2010-03-21	Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag	Crystalline mycophenolate sodium
GB0419355D0 (en) *	2004-08-31	2004-09-29	Novartis Ag	Organic compounds
US20080176937A1 (en) *	2007-01-23	2008-07-24	Apotex Fermentation Inc.	Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
PL2349220T3 (pl) *	2008-10-09	2012-12-31	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny
CN101756958B (zh) *	2008-11-10	2011-07-20	鲁南制药集团股份有限公司	一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
JP5658751B2 (ja)	2009-07-10	2015-01-28	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	１−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンのための結晶化方法
EA201270544A1 (ru) *	2009-10-13	2012-09-28	Тева Фармасьютикал Индастриз Лтд.	Композиции с отсроченным высвобождением
EP2528894A1 (de)	2010-01-27	2012-12-05	Arena Pharmaceuticals, Inc.	Verfahren zur herstellung von (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)essigsäure und salzen daraus
NZ703128A (en)	2010-05-11	2016-04-29	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
CN103880800A (zh) *	2010-11-16	2014-06-25	北京京卫信康医药科技发展有限公司	麦考酚酸钠的新晶型及其制备方法
CN103880799A (zh) *	2010-11-16	2014-06-25	北京京卫信康医药科技发展有限公司	麦考酚酸钠的新晶型及其制备方法
WO2012140120A1 (en)	2011-04-13	2012-10-18	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
TWI582078B (zh) *	2013-01-23	2017-05-11	北京貝美拓新藥研發有限公司	抑制脯氨酸羥化酶活性的化合物的晶型及其應用
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
LT3394051T (lt) *	2015-12-21	2020-08-10	Janssen Pharmaceutica N.V.	Kristalizacijos procedūra, skirta kanagliflozino hemihidrato kristalų gavimui
CN110520124A (zh)	2017-02-16	2019-11-29	艾尼纳制药公司	用于治疗原发性胆汁性胆管炎的化合物和方法
KR20190113955A (ko)	2017-02-16	2019-10-08	아레나 파마슈티칼스, 인크.	장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN108727317A (zh) *	2017-04-25	2018-11-02	鲁南制药集团股份有限公司	一种麦考酚酸的晶型物
CN108727318A (zh) *	2017-04-25	2018-11-02	鲁南制药集团股份有限公司	麦考酚酸的晶型物
JP7397011B2 (ja)	2018-06-06	2023-12-12	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態を治療する方法
CN110922371B (zh) *	2019-12-27	2020-08-11	广东蓝宝制药有限公司	一种m2晶型麦考酚钠的制备方法
CN120168469A (zh)	2020-05-18	2025-06-20	诺华股份有限公司	Lnp023的结晶形式
US20250296904A1 (en) *	2022-05-31	2025-09-25	Honshu Chemical Industry Co., Ltd.	Crystal of 4,4'-bis(1,1-bis(4-hydroxy-3-methylphenyl)ethyl)biphenyl and method for producing the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US158835A (en) *		1875-01-19		Improvement in mortising-tools
GB935432A (en) *	1958-05-29	1963-08-28	Secr Aviation	Improvements in the manufacture of crystalline substances
US3187039A (en) *	1962-10-19	1965-06-01	Commercial Solvents Corp	Method for changing the crystal habit of monosodium glutamate
US3183263A (en) *	1962-10-19	1965-05-11	Commercial Solvents Corp	Method for changing the crystal habit of mono-sodium glutamate
US3352906A (en) *	1963-02-04	1967-11-14	Charles R Parkerson	Habit modification and preparation of single crystal triglycine sulfate
GB1157099A (en) *	1966-09-27	1969-07-02	Ici Ltd	Fermentation Process
GB1157100A (en) *	1966-09-27	1969-07-02	Ici Ltd	Pharmaceutical Compositions
US3770390A (en) *	1971-02-26	1973-11-06	Dow Chemical Co	Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) *	1980-04-21	1981-03-31	Allied Chemical Corporation	Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en)	1980-06-08	1983-11-30	Yeda Res & Dev	Resolution of amino acids
JPS5875194A (ja) *	1981-10-30	1983-05-06	株式会社日立製作所	マトリクス表示装置及び駆動方法
JPS59232916A (ja) *	1983-06-16	1984-12-27	Shiraishi Chuo Kenkyusho:Kk	針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en)	1985-11-12	1995-12-08	Yeda Res & Dev	Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja)	1987-12-25	1995-05-17	東レ株式会社	有機化合物結晶の製造方法
EP0582452B1 (de) *	1992-08-04	1998-10-14	Toda Kogyo Corp.	Granulierte Teilchen für magnetische Teilchen für magnetische Aufzeichnung und Verfahren für ihre Herstellung
BR9407469A (pt)	1993-09-15	1996-11-12	Syntex Inc	Micofenolato mofetil anidro cristalino e formulação intravenosa do mesmo
JPH09209297A (ja) *	1996-01-26	1997-08-12	Nippon Paper Ind Co Ltd	艶消し軽量塗工紙及びその製造方法
KR100491274B1 (ko) *	1996-04-12	2005-09-05	노파르티스 아게	미코페놀레이트의장용코팅된약제조성물
ID18663A (id)	1996-04-12	1998-04-30	Novartis Ag	Komposisi farmasi berlapis enterik
FR2780403B3 (fr) *	1998-06-24	2000-07-21	Sanofi Sa	Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en)	2003-01-20	2003-02-19	Novartis Ag	Organic compounds

2003
- 2003-01-20 GB GBGB0301259.8A patent/GB0301259D0/en not_active Ceased
2004
- 2004-01-19 KR KR1020107024515A patent/KR20100120321A/ko not_active Ceased
- 2004-01-19 RU RU2005126328/04A patent/RU2388757C2/ru active
- 2004-01-19 AT AT04703158T patent/ATE546132T1/de active
- 2004-01-19 KR KR1020097022060A patent/KR20090115821A/ko not_active Ceased
- 2004-01-19 PT PT04703158T patent/PT1592401E/pt unknown
- 2004-01-19 NZ NZ541073A patent/NZ541073A/en not_active IP Right Cessation
- 2004-01-19 KR KR1020057013313A patent/KR100855149B1/ko not_active Expired - Lifetime
- 2004-01-19 SI SI200431859T patent/SI1592401T1/sl unknown
- 2004-01-19 ES ES04703158T patent/ES2382035T3/es not_active Expired - Lifetime
- 2004-01-19 SG SG200700660-4A patent/SG155046A1/en unknown
- 2004-01-19 CN CNA2008101443548A patent/CN101333201A/zh active Pending
- 2004-01-19 EP EP10177718A patent/EP2308471A1/de not_active Withdrawn
- 2004-01-19 MY MYPI20040142A patent/MY148297A/en unknown
- 2004-01-19 AR ARP040100142A patent/AR043343A1/es unknown
- 2004-01-19 PL PL376525A patent/PL376525A1/pl not_active Application Discontinuation
- 2004-01-19 PE PE2011000069A patent/PE20110276A1/es active IP Right Grant
- 2004-01-19 DK DK04703158.8T patent/DK1592401T3/da active
- 2004-01-19 TW TW093101302A patent/TWI325785B/zh not_active IP Right Cessation
- 2004-01-19 CA CA2706900A patent/CA2706900A1/en not_active Abandoned
- 2004-01-19 MX MXPA05007691A patent/MXPA05007691A/es active IP Right Grant
- 2004-01-19 KR KR1020077016703A patent/KR20070087181A/ko not_active Ceased
- 2004-01-19 PL PL393385A patent/PL213192B1/pl unknown
- 2004-01-19 AU AU2004206731A patent/AU2004206731B2/en not_active Expired
- 2004-01-19 JP JP2005518641A patent/JP4549976B2/ja not_active Expired - Fee Related
- 2004-01-19 EP EP04703158A patent/EP1592401B1/de not_active Revoked
- 2004-01-19 CN CN200480002455A patent/CN100595199C/zh not_active Expired - Lifetime
- 2004-01-19 KR KR1020097022061A patent/KR101129105B1/ko not_active Expired - Lifetime
- 2004-01-19 US US10/541,504 patent/US20060122265A1/en not_active Abandoned
- 2004-01-19 PE PE2004000074A patent/PE20040826A1/es not_active Application Discontinuation
- 2004-01-19 BR BR0406827-0A patent/BRPI0406827A/pt not_active Application Discontinuation
- 2004-01-19 WO PCT/EP2004/000354 patent/WO2004064806A2/en not_active Ceased
- 2004-01-19 CA CA2509796A patent/CA2509796C/en not_active Expired - Lifetime
- 2004-01-20 CL CL200400073A patent/CL2004000073A1/es unknown
2005
- 2005-05-31 ZA ZA200504442A patent/ZA200504442B/en unknown
- 2005-06-30 IL IL169484A patent/IL169484A/en active IP Right Grant
- 2005-07-15 EC EC2005005918A patent/ECSP055918A/es unknown
- 2005-07-25 CO CO05072728A patent/CO5580738A2/es not_active Application Discontinuation
- 2005-08-16 NO NO20053846A patent/NO20053846L/no not_active Application Discontinuation
2008
- 2008-12-18 US US12/337,663 patent/US8008511B2/en not_active Expired - Lifetime
2011
- 2011-08-04 US US13/198,022 patent/US8124795B2/en not_active Expired - Lifetime
2012
- 2012-05-14 CY CY20121100450T patent/CY1112772T1/el unknown
2016
- 2016-02-15 AR ARP160100409A patent/AR103711A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
HK1084874A1 (en)	2006-08-11
ES2382035T3 (es)	2012-06-04
BRPI0406827A (pt)	2005-12-27
KR100855149B1 (ko)	2008-08-28
CN100595199C (zh)	2010-03-24
CN101333201A (zh)	2008-12-31
US8124795B2 (en)	2012-02-28
NO20053846L (no)	2005-08-16
US20110288313A1 (en)	2011-11-24
CO5580738A2 (es)	2005-11-30
GB0301259D0 (en)	2003-02-19
SI1592401T1 (sl)	2012-05-31
PT1592401E (pt)	2012-05-10
TWI325785B (en)	2010-06-11
MXPA05007691A (es)	2005-09-30
ZA200504442B (en)	2006-02-22
EP1592401A2 (de)	2005-11-09
CY1112772T1 (el)	2016-02-10
PE20110276A1 (es)	2011-05-27
CN1738605A (zh)	2006-02-22
MY148297A (en)	2013-03-29
AR103711A2 (es)	2017-05-31
WO2004064806A3 (en)	2004-10-28
CL2004000073A1 (es)	2005-01-14
RU2388757C2 (ru)	2010-05-10
JP4549976B2 (ja)	2010-09-22
AU2004206731A8 (en)	2004-08-05
JP2006515016A (ja)	2006-05-18
EP2308471A1 (de)	2011-04-13
PL213192B1 (pl)	2013-01-31
AU2004206731B2 (en)	2008-03-20
EP1592401B1 (de)	2012-02-22
PE20040826A1 (es)	2004-12-23
US20060122265A1 (en)	2006-06-08
KR20050096940A (ko)	2005-10-06
RU2005126328A (ru)	2006-07-27
KR20070087181A (ko)	2007-08-27
IL169484A (en)	2016-03-31
CA2509796A1 (en)	2004-08-05
WO2004064806A2 (en)	2004-08-05
PL376525A1 (pl)	2006-01-09
TW200505505A (en)	2005-02-16
US20090209639A1 (en)	2009-08-20
KR20100120321A (ko)	2010-11-15
US8008511B2 (en)	2011-08-30
ECSP055918A (es)	2005-11-22
KR20090115898A (ko)	2009-11-09
PL393385A1 (pl)	2011-03-14
CA2706900A1 (en)	2004-08-05
AU2004206731A1 (en)	2004-08-05
KR20090115821A (ko)	2009-11-06
DK1592401T3 (da)	2012-05-21
CA2509796C (en)	2010-09-14
SG155046A1 (en)	2009-09-30
IL169484A0 (en)	2007-07-04
AR043343A1 (es)	2005-07-27
NZ541073A (en)	2008-12-24
KR101129105B1 (ko)	2012-04-12

Publication	Publication Date	Title
DK1592401T3 (da)	2012-05-21	Fremgangsmåde til ændring af medikamentkrystaldannelsen af mycophenolat-natriumsalt
DE602004026576D1 (de)	2010-05-27	Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz
DE60336326D1 (de)	2011-04-21	Verfahren zur herstellung des calciumsalzes von rosuvastatin
DE60321130D1 (de)	2008-07-03	Variation von parametern zur neurostimulation
DE602004026008D1 (de)	2010-04-29	Verfahren zur Herstellung von Flexodruckformen
EP1514436A4 (de)	2008-02-20	Zweischwellen-aufwärtsstreckenratensteuerung zur ermöglichung von aufwärtsstrecken-einteilung
NO20041082L (no)	2004-03-15	Fremgangsmater for fremstilling av kalsiumsaltformer av statiner
DE60234897D1 (de)	2010-02-11	Tintenzusatzmittel zur Verbesserung von Verzögerung der Tintentropfen
DE60330341D1 (de)	2010-01-14	Verfahren zur herstellung von wabenstrukturen
DE502004005616D1 (de)	2008-01-10	Keramisches filterelement zur reinigung von wasser
DE602004021214D1 (de)	2009-07-09	Regelstrecke mit Kompensation von Störgrössen
DE60313837D1 (de)	2007-06-28	Nichtionische Zusätze zur Kontrolle der Pfützenbildung von Tintenstrahldruckertinten
EP1523700A4 (de)	2008-07-09	Verfahren zur kompensation von geringem tonerverbrauch
DE60300252D1 (de)	2005-02-03	Verfahren zur industriellen Herstellung von 5-Amino-3-carboxymethyl-4-cyano-2-thiphencarboxydimethylester
DE60220554D1 (de)	2007-07-19	Mikrowelleninduzierter prozess zur herstellung von substituierten 4-vinylphenolen
DE60234275D1 (de)	2009-12-17	Verfahren zur herstellung von diglyceriden
DE602004021052D1 (de)	2009-06-25	Herstellungsverfahren von Xylylendiamin
DE602006003094D1 (de)	2008-11-20	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602004014217D1 (de)	2008-07-17	Verfahren für die Wiedergewinnung von Land Vorvertiefung
DE50211253D1 (de)	2008-01-03	Verfahren zur Herstellung von Makrokapseln
DE60232935D1 (de)	2009-08-27	Herstellungsverfahren von Druckeinheiten
DE60318444D1 (de)	2008-02-14	Verfahren zur herstellung von nevirapin
DE602004031556D1 (de)	2011-04-07	Neue kristalline formen von 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-n-hydroxyethylimidazoä1,2-aüpyridin-6-carbonsäureamidmesylatsalz
DE60218352D1 (de)	2007-04-05	Verfahren zur gewinnung von natriumarmem salz aus bitterwässern
DE60336986D1 (de)	2011-06-16	Verfahren zur herstellung von biarylverbindungen